Hepatitis B virus (HBV) infection is highly endemic
in Senegal. Vaccination of all children against HBV was introduced in 1999 and
included in Expanded Programme on Immunisation in 2005. The aim of this study
was to assess the prevalence and immune status against HBV in patients received
at Pasteur Institut in Dakar, Senegal. Methods: Between January 2016 and
December 2020, patients aged between 1 and 96 years received laboratory were
included in the study. Serum samples were analysed for HBV serology (HBs
antigen: HBsAg, HBs antibody: HBsAb and HBc antibody: HBcAb) using ARCHITECT? analyser. Patients with anti-HBs antibody levels (HBsAb≥10 IU/l) were considered seroprotected against HBV. Results: A
total of 5629 patients were analysed with a mean age of 39 years and extremes
from 1 to 96 years. The most represented age group was 31-45 years with 38.4%. HBsAg was present in 520 patients (9.2%) and was
signed by sex and age group. Anti-HBc antibodies were found in 52.7% of
patients and 1603 (28.48%) had isolated anti-HBs antibodies reflecting
proportion of people vaccinated at the time of the study. However, 2143
patients (41.9%) had no seroprotection (HBsAb<10 IU/L) and 640 (12.6%) had strong seroprotection defined as HBsAb>1000 IU/L. Conclusion: Our results show a significant presence of
virus in
References
[1]
Schweitzer, A., Horn, J., Mikolajczyk, R.T., Krause, G. and Ott, J.J. (2015) Estimations of Worldwide Prevalence of Chronic Hepatitis B Virus Infection: A Systematic Review Of Data Published between 1965 and 2013. Lancet, 386, 1546-1555. https://doi.org/10.1016/S0140-6736(15)61412-X
[2]
Stanaway, J.D, Flaxman, A.D, Naghavi, M., Fitzmaurice, C., Vos, T., Abubakar, I. et al. (2016) The Global Burden of Viral Hepatitis from 1990 to 2013: Findings from the Global Burden of Disease Study 2013. Lancet, 388, 1081-1088. https://doi.org/10.1016/S0140-6736(16)30579-7
[3]
WHO (2016) Combattre les hépatites B et C pour parvenir à leur élimination d’ici 2030. https://apps.who.int/iris/bitstream/handle/10665/206453/WHO_HIV_2016.04_eng.pdf
[4]
WHO (2018) Hépatite B: Principaux Repères. https://www.who.int/fr/news-room/fact-sheets/detail/hepatitis-b
[5]
Modi, A.A. and Feld, J.J. (2007) Viral Hepatitis and HIV in Africa. AIDS Reviews, 9, 25-39.
[6]
Rey-Cuille, M.-A., Njouom, R., Bekondi, C., Seck, A., Gody, C., Bata, P., et al. (2013) Hepatitis B Virus Exposure during Childhood in Cameroon, Central African Republic and Senegal after the integration of HBV Vaccine in the Expanded Program on Immunization. The Pediatric Infectious Disease Journal, 32, 1110-1115. https://doi.org/10.1097/INF.0b013e31829be401
[7]
Rey-Cuille, M.-A., Seck, A., Njouom, R., Chartier, L., Sow, H.D., Mamadou, N., et al. (2012) Low Immune Response to Hepatitis B Vaccine among Children in Dakar, Senegal. PLOS ONE, 7, e38153. https://doi.org/10.1371/journal.pone.0038153
[8]
Komatsu, H. (2014) Hepatitis B Virus: Where Do We Stand and What Is The Next Step for Eradication? World Journal of Gastroenterology, 20, 8998-9016.
[9]
Maupas, P., Chiron, J., Goudeau, A., Coursaget, P. and Perrin, J. (1981) Epidémiologie et conséquences pathologiquesdu portage chronique du virus de l’hépatite B au Mali. Bulletin de la Société de Pathologie Exotique, 74, 722-732. https://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=PASCAL82X0255844
[10]
Kakisingi, C.N., Mukuku, O., Matanda, S.K., Manika, M.M., Kyabu, V.K., Kasamba, E.I., et al. (2016) Profil épidémiologique et séroprévalence des donneurs de sang aux cliniques universitaires de Lubumbashi, République Démocratique du Congo. Pan African Medical Journal, 23, Article 175. https://doi.org/10.11604/pamj.2016.23.175.8480
[11]
Buseri, F.I., Muhibi, M.A. and Jeremiah, Z.A. (2009) Sero-Epidemiology of Transfusion-Transmissible Infectious Diseases among Blood Donors in Osogbo, South- West Nigeria. Blood Transfusion, 7, 293-299.
[12]
Kra, O., N’dri, N., Ouattara, B., Kadjo, K., Aba, T. and Bissagnéné, E. (2012) Prévalence du portage de l’antigène HBs dans une population de recrues de la gendarmerie nationale de Côte d’Ivoire en 2008. Médecine et Santé Tropicales, 22, 219-220.
[13]
Nagalo, B.M., Bisseye, C., Sanou, M., Kienou, K., Nebié, Y.K., Kiba, A., et al. (2012) Seroprevalence and Incidence of Transfusion-Transmitted Infectious Diseases among Blood Donors from Regional Blood Transfusion Centres in Burkina Faso, West Africa. Tropical Medicine & International Health, 17, 247-253. https://doi.org/10.1111/j.1365-3156.2011.02902.x
[14]
World Health Assembly (2001) Global Health Security—Epidemic Alert and Response: Report by the Secretariat. World Health Organization, Geneva. https://apps.who.int/iris/handle/10665/78718
[15]
WHO (2017) Global Hepatitis Report, 2017. World Health Organization, Geneva. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1.Kra
[16]
Bougoudogo, F., Traoré, S. and Niangaly, A. (2001) Rapport sur la prévalence des marqueurs de l’infection par le virus de l’hépatite B au Mali. Journal of Medical Virology, 65, 1-5.
[17]
Tounkara, A., Sarro, Y.S., Kristensen, S., Dao, S., Diallo, H., Diarra, B., et al. (2009) Seroprevalence of HIV/HBV Coinfection in Malian Blood Donors. Journal of the International Association of Physicians in AIDS Care, 8, 47-51. https://doi.org/10.1177/1545109708330118
Denis, F., Abitbol, V. and Aufrère, A. (2004) Evolution of Strategy and Coverage Rates for Hepatitis B Vaccination in France, a Country with Low Endemicity. Médecine et Maladies Infectieuses, 34, 149-158. https://doi.org/10.1016/j.medmal.2003.12.010
[20]
Bwogi, J., Braka, F., Makumbi, I., Mishra, V., Bakamutumaho, B., Nanyunja, M., et al. (2009) Hepatitis B Infection Is Highly Endemic in Uganda: Findings from a National Serosurvey. African Health Sciences, 9, 98-108.
[21]
Centers for Disease Control and Prevention (CDC) (2004) Hepatitis B Vaccination Coverage among Adults—United States. Morbidity and Mortality Weekly Report, 55, 509-511.
[22]
Topuridze, M., Butsashvili, M., Kamkamidze, G., Kajaia, M., Morse, D. and McNutt, L.A. (2010) Barriers to Hepatitis B Vaccine Coverage among Healthcare Workers in the Republic of Georgia: An International Perspective. Infection Control & Hospital Epidemiology, 31, 158-164. https://doi.org/10.1086/649795
[23]
Programme National de Lutte contre les Hépatites au Sénégal (PNLH) (2018) La réponse du Sénégal. https://hepatites.sn/
[24]
Jack, A.D., Hall, A.J., Maine, N., Mendy, M. and Whittle, H.C. (1999) What Level of Hepatitis B Antibody Is Protective? The Journal of Infectious Diseases, 179, 489-492. https://doi.org/10.1086/314578
[25]
Coppola, N., Corvino, A.R., De Pascalis, S., Signoriello, G., Di Fiore, E., Nienhaus, A., et al. (2015) The Long-Term Immunogenicity of Recombinant Hepatitis B Virus (HBV) Vaccine: Contribution of Universal HBV Vaccination in Italy. BMC Infectious Diseases, 15, Article No. 149. https://doi.org/10.1186/s12879-015-0874-3
[26]
Xiao, J., Zhang, J., Wu, C., Shao, X., Peng, G., Peng, Z., et al. (2012) Impact of Hepatitis B Vaccination among Children in Guangdong Province, China. International Journal of Infectious Diseases, 16, 692-696. https://doi.org/10.1016/j.ijid.2012.05.1027
[27]
Greengold, B., Nyamathi, A., Kominski, G., Wiley, D., Lewis, M.A., Hodge, F., et al. (2009) Cost-Effectiveness Analysis of Behavioral Interventions to Improve Vaccination Compliance in Homeless Adults. Vaccine, 27, 718-725. https://doi.org/10.1016/j.vaccine.2008.11.031
[28]
Siegrist, C.A. (2000) Vaccination in the Neonatal Period and Early Infancy. International Reviews of Immunology, 19, 195-219. https://doi.org/10.3109/08830180009088505
[29]
Siegrist, C.A., Córdova, M., Brandt, C., Barrios, C., Berney, M., Tougne, C., et al. (1998) Determinants of Infant Responses to Vaccines in Presence of Maternal Antibodies. Vaccine, 16, 1409-1414. https://doi.org/10.1016/S0264-410X(98)00100-5
